Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial

Richard M. Bergenstal; Jill P. Crandall; Samuel P. Rosin; N. Butera; A. Bantle; Cyrus Desouza; Elizabeth Duran-Valdez; Stephanie V. Hall; William H. Herman; Mary L. Johnson; Violet S. Lagari; Mary E. Larkin; Larry Phillips; Holly Willis; Heidi Krause-Steinrauf; J.P. Crandall; M.D. McKee; S. Behringer-Massera; J. Brown-Friday; E. Xhori; K. Ballentine-Cargill; S. Duran; H. Estrella; S. Gonzalez de la Torre; J. Lukin; Larry Phillips; E. Burgess; D. Olson; M. Rhee; P. Wilson; T.S. Raines; J. Boers; J. Costello; M. Maher-Albertelli; R. Mungara; L. Savoye; C.A. White; C. Gullett; L. Holloway; F. Morehead; S. Person; M. Sibymon; S. Tanukonda; C. Adams; A. Ross; A. Balasubramanyam; R. Gaba; E. Gonzalez Hattery; A. Ideozu; J. Jimenez; G. Montes; C. Wright; P. Hollander; E. Roe; A. Jackson; A. Smiley; P. Burt; L. Estrada; K. Chionh; F. Ismail-Beigi; C. Falck-Ytter; L. Sayyed Kassem; A. Sood; M. Tiktin; T. Kulow; C. Newman; K.A. Stancil; B. Cramer; J. Iacoboni; M.V. Kononets; C. Sanders; L. Tucker; A. Werner; A. Maxwell; G. McPhee; C. Patel; L. Colosimo; A. Krol; R. Goland; J. Pring; L. Alfano; P. Kringas; C. Hausheer; J. Tejada; K. Gumpel; A. Kirpitch; H. Schneier; J.B. Green; H. AbouAssi; R. Chatterjee; M.N. Feinglos; J. English Jones; S.A. Khan; J.B. Kimpel; R.P. Zimmer; M. Furst; B.M. Satterwhite; C.R. Thacker; K. Evans Kreider; C.N. Mariash

doi:10.2337/dc25-3055

April 2, 2026Diabetes Care

Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to compare the continuous glucose monitoring profiles of different glucose-lowering medications in diabetes management.
Analyzed CGM metrics across four glucose-lowering medications
Evaluated %CV (coefficient of variation) for each medication
Assessed achievement of CGM-based glycemic targets
Incretin drugs exhibited the lowest %CV among the medications
Incretin usage resulted in the least occurrences of hypoglycemia
Best achievement of CGM-based glycemic targets was noted with incretin class drugs

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Incretin class drugs had the lowest %CV, the least hypoglycemia, and best achievement of CGM-based glycemic targets. CGM metrics and profiles provide clinical insights, beyond HbA1c, to guide diabetes management.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bergenstal et al. (2026) studied this question.

synapsesocial.com/papers/69d0afc7659487ece0fa5d8e https://doi.org/10.2337/dc25-3055

View at Publisher

Ask AI

Bookmark

Share

Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading